Sanofi - American Depositary Shares (NQ:SNY)

Performance

52-Week Range 8.3% below 52-week high

48.31

39.0752W Low 52.6852W High

1 Week 0.7% below 1-week high

45.581W Low 48.671W High

Sanofi - American Depositary Shares (SNY) traded between $39.07 and $52.68 over the past 52 weeks and last traded at $48.31, 8.3% below its 52-week high. Over the past week it ranged between $45.58 and $48.67.

Past 12 Months

+1.8%

+21.6%

+10.9%

+12.7%

+0.2%

-4.6%

1W +$0.84

1M +$8.57

3M +$4.75

6M +$5.45

YTD +$0.08

1Y -$2.35

SNY was -4.6% over the past year, +12.7% over six months, +0.2% year to date, +1.8% in the last week.

12 Months vs Market

SNY

-4.6%

DIA

+10.7%

SPY

+11.5%

QQQ

+10.9%

IWM

+16.0%

Over the past 12 months SNY returned -4.6% versus DIA (Dow) +10.7%, SPY (S&P 500) +11.5%, QQQ (Nasdaq 100) +10.9% and IWM (Russell 2000) +16.0%.

Volume & Liquidity 0.54× 3-mo avg

Today 1,799,849 3-mo avg 3.4M

5.4M

4.8M

3.4M

YTD

3.5M

3.4M

SNY most recently traded 1,799,849 shares against a 3-month average daily volume of 3.4M.

More News

Sanofi Q3 Earnings Call Highlights ↗

October 30, 2026

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

October 20, 2026

From Teva Pharmaceutical Industries Ltd

Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability ↗

August 27, 2026

Via Chartmill

Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability ↗

August 07, 2026

Via Chartmill

Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality ↗

July 16, 2026

Via Chartmill

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share ↗

October 17, 2026

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

October 14, 2026

From Biotech Insider

Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion ↗

October 01, 2026

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

October 01, 2026

From Regeneron Pharmaceuticals, Inc.

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine ↗

September 22, 2026

Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss ↗

September 20, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? ↗

August 26, 2026

Sanofi Q2 Earnings Call Highlights ↗

July 30, 2026

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.) ↗

July 28, 2026

Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

July 21, 2026

Via FinancialNewsMedia

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026